Provectus Biopharmaceuticals, Inc. (PVCT) added 15.63% to reach $0.04 in the previous trading session. Overall, 3.46 Million shares exchanged hands versus its average trading volume of 2.95 Million shares. The relative volume of the stock is 1.17, while its market cap is $15.65 Million.
Relative Strength Index
The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. The RSI oscillates between zero and 100. Usually the RSI is considered overbought when above 70 and oversold when less than 30.
Relative strength index (RSI-14) for Provectus Biopharmaceuticals, Inc. (PVCT) is at 57.43.
A moving average (MA) is a trend-following or lagging indicator because it is based on past prices. The average is taken over a specific period of time, like 10 days, 20 minutes, 30 weeks, or any time period the trader chooses. There are advantages to using a moving average in your trading, as well options on what type of moving average to use. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders.
A moving average can help cut down the amount of “noise” on a price chart. Look at the direction of the moving average to get a basic idea of which way the price is moving. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range.
Provectus Biopharmaceuticals, Inc. (PVCT)’s distance from 200 day simple moving average is -61.39 percent, its distance from 50 day simple moving average is 63.71 percent, while its distance from 20 day simple moving average is 21.69 percent.
A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year. Many traders and investors view the 52-week high or low as an important factor in determining a stock’s current value and predicting future price movement.
Provectus Biopharmaceuticals, Inc. (PVCT) has a 52-week high of $0.54 and a 52-week low of $0.01.
In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. Ultimately, through all this investigation into the company’s performance the analyst decides whether their stock is a “buy,” sell” or hold.”
The stock’s currently has an analysts’ mean recommendation of 2. Provectus Biopharmaceuticals, Inc. was covered by a number of analysts recently, 0 rated the stock as Strong Buy, 0 rated Buy, 0 rated Hold, 0 rated sell and 0 gave an Underperform.
Rodman & Renshaw Upgrade its coverage for Provectus Biopharmaceuticals, Inc. (PVCT) in a note sent to investors on 7-Apr-09. The research firm Upgrade the stock to Mkt Outperform. Moreover, Rodman & Renshaw issued Initiated rating for the stock on 27-Nov-07.
A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. Trend analysis is based on historical data about the stock’s performance given the overall trends of the market and particular indicators within the market.
Provectus Biopharmaceuticals, Inc. shares decreased -25.39 percent over the past week and rose 82.55 percent over the previous month. The stock climbed 156.89 percent over the past quarter, while declined -55.82 percent over the past six months.